COVID-19 also ushered in historic clinical and manufacturing partnerships among pharmaceutical companies to accelerate the pace of innovation and bring the latest technologies to market. From Pfizer and BioNTech joining forces to develop the first COVID-19 vaccine to Merck volunteering to produce Johnson & Johnson’s single-dose vaccine, the data suggests Americans have an acute awareness of these key partnerships, and 42% expect pharmaceutical companies to keep working together in the future to develop more or better COVID-19 preventive care and treatments. Notably, this expectation for collaboration extends beyond the COVID-19 space: 39% say they expect pharmaceutical companies to keep working together to speed up the pace of innovation in other areas such as cancer, other infectious diseases, and more.